PMID: 9449258Feb 4, 1998Paper

Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice

Antimicrobial Agents and Chemotherapy
T OtsuboS Kohno

Abstract

We investigated the efficacy of long-circulating immunoliposomal amphotericin B (AmB) against invasive pulmonary aspergillosis in mice using three types of liposomal AmB: conventional liposomal AmB (AmBisome), a long-circulating liposomal AmB and prepared by coating the liposome surface with polyethylene glycol (PEG; PEG-L-AmB), long-circulating immunoliposomal AmB (34A-PEG-L-AmB). The survival rates for mice with invasive pulmonary aspergillosis treated with an intravenous dose of 2 mg of AmBisome, PEG-L-AmB, or 34A-PEG-L-AmB per kg of body weight were 16.7, 83.3, and 100%, respectively. Treatment with 34A-PEG-L-AmB produced a marked reduction in the number of Aspergillus fumigatus organisms in the lungs. Pharmacokinetic studies showed the presence of high AmB concentrations in the plasma of mice treated with PEG-L-AmB (40.8 microg/ml) and in the lungs of mice treated with 34A-PEG-L-AmB (42.3 microg/g). We conclude that 34A-PEG-L-AmB, a long-circulating immunoliposomal AmB, is a promising form of AmB against invasive pulmonary aspergillosis.

References

Sep 1, 1990·The American Review of Respiratory Disease·J DefaveriJ R Graybill
Nov 1, 1990·Journal of Pharmaceutical Sciences·K MaruyamaL Huang
Dec 1, 1989·The Journal of Experimental Medicine·M BrüggemannM S Neuberger
Jul 1, 1988·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·M C RorvikS J Kennel
May 1, 1982·The Journal of Infectious Diseases·J R GraybillW E Magee
May 1, 1994·The Journal of Infection·D W Denning
May 1, 1994·The Journal of Infection·R J Hay

❮ Previous
Next ❯

Citations

Jul 2, 2005·Expert Opinion on Emerging Drugs·Elisabeth J Ruijgrok, Jaques F G M Meis
Jul 2, 2008·Expert Opinion on Drug Delivery·Michael D VanAuker, Elizabeth Hood
Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M Ellis
Feb 15, 2019·MSphere·Suresh AmbatiRichard B Meagher
Jun 1, 2017·Frontiers in Microbiology·Guillaume Desoubeaux, Carolyn Cray
Jun 27, 2000·International Journal of Pharmaceutics·K MoribeM Iwatsuru
Apr 9, 1999·Clinical Microbiology Reviews·J P Latgé

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.